Ischemic Heart Disease (IHD) Drugs Global Market Report 2025

Description

Ischemic heart disease (IHD) drugs refer to medications employed in the management and treatment of a condition characterized by reduced blood flow to the heart muscle, often due to narrowing of the coronary arteries. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The primary drug classes encompassed by ischemic heart disease (IHD) drugs include anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents targeting and reducing abnormal lipid levels (such as cholesterol and triglycerides) in the bloodstream to mitigate the risk of cardiovascular disease. These drugs are utilized in the treatment of various conditions, including angina pectoris and myocardial infarction, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The ischemic heart disease (IHD) drugs market research report is one of a series of new reports from The Business Research Company that provides ischemic heart disease (IHD) drugs market statistics, including ischemic heart disease (IHD) drugs industry global market size, regional shares, competitors with a ischemic heart disease (IHD) drugs market share, detailed ischemic heart disease (IHD) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (IHD) drugs industry. This ischemic heart disease (IHD) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ischemic heart disease (IHD) drugs market size has grown strongly in recent years. It will grow from $6.36 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies.

The ischemic heart disease (IHD) drugs market size is expected to see steady growth in the next few years. It will grow to $7.86 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs.

The increasing rates of obesity and diabetes are anticipated to drive the growth of the ischemic heart disease (IHD) drugs market in the coming years. Diabetes, a chronic metabolic disorder leading to high blood glucose levels, and obesity, a condition marked by excessive body fat that can harm health, are both key risk factors for cardiovascular issues. IHD drugs are frequently prescribed for individuals with obesity and diabetes to manage cardiovascular risk factors like hypertension and dyslipidemia, thereby reducing the likelihood of ischemic heart disease. For example, the World Obesity Federation, a UK-based organization working to address obesity worldwide, reported in 2022 that by 2030, one billion people globally-including 1 in 5 women and 1 in 7 men-will be living with obesity. Similarly, in June 2024, the National Health Service (NHS) in the UK identified an additional 549,000 people in England at risk of type 2 diabetes, bringing the total number of individuals with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, up nearly 20% from 3,065,825 in 2022. This rising prevalence of obesity and diabetes is thus driving growth in the IHD drugs market.

The increasing incidence of heart failure is another factor expected to contribute to the growth of the ischemic heart disease (IHD) drug market. Heart failure, a chronic condition where the heart muscle cannot pump enough blood, often leads to symptoms such as fatigue and shortness of breath. Ischemic heart disease drugs play a crucial role in treating heart failure by reducing risk factors and symptoms associated with IHD. These medications can be particularly beneficial for heart failure patients with reduced ejection fractions and high resting heart rates. For instance, data from the Heart Failure Society of America in September 2023 indicates that 6.7 million Americans over 20 years of age have heart failure, and this prevalence is expected to increase to 8.5 million Americans by 2030. The rising incidence of heart failure is a key driver for the growth of the ischemic heart disease (IHD) drug market.

Leading companies in the ischemic heart disease (IHD) drugs market are increasingly focusing on developing innovative myosin inhibitors to strengthen their competitive position. Cardiac myosin inhibitors work by reducing myosin activity in the heart muscle, thereby lowering contraction force. This approach is particularly useful for treating conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening hinders heart function. For example, in April 2022, Bristol Myers Squibb, a U.S.-based pharmaceutical company, introduced Camzyos (mavacamten), the first cardiac myosin inhibitor approved to treat adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive HCM, aiming to enhance functional capacity and relieve symptoms. Camzyos acts as a selective, allosteric, and reversible inhibitor of cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and cardiac filling pressures, which helps alleviate dynamic left ventricular outflow tract (LVOT) obstruction.

In March 2024, Denmark-based pharmaceutical company Novo Nordisk acquired Cardior Pharmaceuticals for an undisclosed sum. This acquisition marks a key step in Novo Nordisk's strategy to build and expand its portfolio in cardiovascular disease, a leading cause of death globally. Cardior Pharmaceuticals, based in Germany, specializes in manufacturing cardiovascular drugs for ischemic heart disease (IHD).

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ischemic heart disease (IHD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ischemic Heart Disease (IHD) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ischemic heart disease (ihd) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ischemic heart disease (ihd) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ischemic heart disease (ihd) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Anti-Dyslipidemic Drugs; Calcium Channel Blockers; Beta-Blockers; Angiotensin-converting enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Vasodilators; Antithrombotic Agents
2) By Disease Class: Angina Pectoris; Myocardial Infarction
3) By End User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins; Fibrates; Niacin; Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers; Non-Selective Beta-Blockers; Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril; Lisinopril; Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan; Valsartan; Irbesartan
6) By Vasodilators: Nitroglycerin; Isosorbide Dinitrate; Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs; Anticoagulants
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r28371

1. Executive Summary

2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

4. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Ischemic Heart Disease (IHD) Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Ischemic Heart Disease (IHD) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Ischemic Heart Disease (IHD) Drugs Market Growth Rate Analysis
5.4. Global Ischemic Heart Disease (IHD) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Ischemic Heart Disease (IHD) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Ischemic Heart Disease (IHD) Drugs Total Addressable Market (TAM)

6. Ischemic Heart Disease (IHD) Drugs Market Segmentation

6.1. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Dyslipidemic Drugs
Calcium Channel Blockers
Beta-Blockers
Angiotensin-converting enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasodilators
Antithrombotic Agents
6.2. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angina Pectoris
Myocardial Infarction
6.3. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Statins
Fibrates
Niacin
Cholesterol Absorption Inhibitors
6.5. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dihydropyridines
Non-Dihydropyridines
6.6. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardioselective Beta-Blockers
Non-Selective Beta-Blockers
Vasodilating Beta-Blockers
6.7. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enalapril
Lisinopril
Ramipril
6.8. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Losartan
Valsartan
Irbesartan
6.9. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nitroglycerin
Isosorbide Dinitrate
Hydralazine
6.10. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiplatelet Drugs
Anticoagulants

7. Ischemic Heart Disease (IHD) Drugs Market Regional And Country Analysis

7.1. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market

8.1. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ischemic Heart Disease (IHD) Drugs Market

9.1. China Ischemic Heart Disease (IHD) Drugs Market Overview
9.2. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ischemic Heart Disease (IHD) Drugs Market

10.1. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ischemic Heart Disease (IHD) Drugs Market

11.1. Japan Ischemic Heart Disease (IHD) Drugs Market Overview
11.2. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ischemic Heart Disease (IHD) Drugs Market

12.1. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ischemic Heart Disease (IHD) Drugs Market

13.1. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ischemic Heart Disease (IHD) Drugs Market

14.1. South Korea Ischemic Heart Disease (IHD) Drugs Market Overview
14.2. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ischemic Heart Disease (IHD) Drugs Market

15.1. Western Europe Ischemic Heart Disease (IHD) Drugs Market Overview
15.2. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ischemic Heart Disease (IHD) Drugs Market

16.1. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ischemic Heart Disease (IHD) Drugs Market

17.1. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ischemic Heart Disease (IHD) Drugs Market

18.1. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ischemic Heart Disease (IHD) Drugs Market

19.1. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ischemic Heart Disease (IHD) Drugs Market

20.1. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market

21.1. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market Overview
21.2. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ischemic Heart Disease (IHD) Drugs Market

22.1. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ischemic Heart Disease (IHD) Drugs Market

23.1. North America Ischemic Heart Disease (IHD) Drugs Market Overview
23.2. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ischemic Heart Disease (IHD) Drugs Market

24.1. USA Ischemic Heart Disease (IHD) Drugs Market Overview
24.2. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ischemic Heart Disease (IHD) Drugs Market

25.1. Canada Ischemic Heart Disease (IHD) Drugs Market Overview
25.2. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ischemic Heart Disease (IHD) Drugs Market

26.1. South America Ischemic Heart Disease (IHD) Drugs Market Overview
26.2. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ischemic Heart Disease (IHD) Drugs Market

27.1. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ischemic Heart Disease (IHD) Drugs Market

28.1. Middle East Ischemic Heart Disease (IHD) Drugs Market Overview
28.2. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ischemic Heart Disease (IHD) Drugs Market

29.1. Africa Ischemic Heart Disease (IHD) Drugs Market Overview
29.2. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Company Profiles

30.1. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape
30.2. Ischemic Heart Disease (IHD) Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Ischemic Heart Disease (IHD) Drugs Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca PLC
31.5. GSK PLC
31.6. Eli Lilly and Company
31.7. Boehringer Ingelheim International GmbH
31.8. Viatris Inc.
31.9. Baxter International Inc.
31.10. Teva Pharmaceutical Industries Ltd.
31.11. Sandoz Inc.
31.12. Sun Pharmaceutical Industries Limited
31.13. Dr. Reddy's Laboratories Ltd.
31.14. Cipla Limited
31.15. Lupin Limited

32. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

34. Recent Developments In The Ischemic Heart Disease (IHD) Drugs Market

35. Ischemic Heart Disease (IHD) Drugs Market High Potential Countries, Segments and Strategies

35.1 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer